Palo Alto Networks, Inc. (NASDAQ:PANW – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the forty-two analysts that are covering the company, Marketbeat Ratings reports.

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

In a report released yesterday, Mason Carrico from Stephens maintained a Buy rating on Illumina (ILMN – Research Report), with a price target ...

RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

TD Cowen analyst Daniel Brennan maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $140.00. The ...

Barclays views Illumina’s (ILMN) guidance last night as largely as expected. The bulls are going to defend the stock on China being de-risked, ...

The cloud-services company offered an upbeat sales outlook, but its quarterly earnings and revenue missed expectations. The stock dropped ...

In a report released today, Luke Sergott from Barclays maintained a Sell rating on Illumina (ILMN – Research Report), with a price target of ...